Tempus Announces 37 Abstracts Accepted for Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that 37 abstracts have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO®) Annual Meeting. The event will take place May 29 - June 3, 2026 in Chicago, Illinois.
“This year’s ASCO Annual Meeting marks a significant milestone for Tempus, as we are presenting our largest collection of accepted research to date, further underscoring the critical role that multimodal data and AI-driven insights play in advancing precision medicine across oncology,” said Kate Sasser, PhD, Chief Scientific Officer at Tempus. “The breadth of our findings demonstrates the tangible impact of these tools in transforming complex real-world data into actionable evidence, helping more patients benefit from the next generation of innovative therapies.”
Research highlights include:
Saturday, May 30, 2026
